Sara Tolaney· @stolaney1 · X·· 2 天前评分90
正文 · 机器翻译
Sara Hurvitz 介绍的 TALENT 试验：术前 TDXd 治疗 HR+ HER2-low 乳腺癌
术前 TDXd：7%
TDXd+AI：3%
TDXd-->TC：9%
加用内分泌治疗以及将化疗与 TDXd 序贯使用，似乎未能改善 pCR
@OncoAlert #ESMO2026
1008 浏览 · 21 赞 · 17 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Sara Tolaney · x.com